Results 51 to 60 of about 2,303 (187)

Potential for Nirsevimab use in Pakistan

Journal of the Pakistan Medical Association
Respiratory Tract Infections can be classified as upper and lower tract infections. Upper tract infections are more common such as laryngitis and pharyngitis, but the infections of lower respiratory tract are more fatal such as influenza or bronchitis.
Muhammad Moaz, Basum Hayat
openaire   +3 more sources

Frequency, Burden and Pathogens of Acute Respiratory Illness in Very Preterm Infants During Infancy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To describe the frequency, burden, and pathogen profile of acute respiratory illnesses (ARIs) in very preterm infants during the first year after neonatal intensive care unit (NICU) discharge. Methods Very preterm infants were followed prospectively (August 2015–January 2017) with monthly assessments of symptoms, medication use, and ...
Patricia De Gouveia Belinelo, Nada Townsi, Naomi R. Hemy, Chisha T. Sikazwe, David W. Smith, Benjamin Stoecklin, J. Jane Pillow, Graham L. Hall, Ingrid A. Laing, Shannon J. Simpson   +9 more
wiley   +1 more source

First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants [PDF]

Respiratory syncytial virus (RSV) predominantly affects young children, with a peak incidence in temperate regions of the northern hemisphere from October to May.
Scarpaleggia M., Rizzo C, Baldo V., Chironna M., Pariani E, Baldo V, Orsi A, Scarpaleggia M, Icardi G, Orsi A., Panatto D, Pariani E., Giuffrida S., Panatto D., Icardi G., Barbone F, Rizzo C., Giuffrida S, Barbone F., Montomoli E., Chironna M, Montomoli E   +20 more
core   +3 more sources

RSV‐Pre‐F Vaccination During Pregnancy and Neonatal Outcomes—A Systematic Review and Meta‐Analysis

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Objectives Respiratory syncytial virus (RSV) is a major cause of infant morbidity and mortality worldwide. Recent preventive strategies include maternal vaccination and monoclonal antibodies. However, maternal RSV vaccination has raised safety concerns due to possible associations with preterm birth.
Niko Leskinen, Marjut Haapanen, Ilari Kuitunen   +2 more
wiley   +1 more source

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Human Vaccines & Immunotherapeutics
The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal ...
Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten   +10 more
doaj   +1 more source

Estimating the National Disease Burden and Economic Burden of Respiratory Syncytial Virus (RSV) in Thailand

Influenza and Other Respiratory Viruses, Volume 20, Issue 9, September 2026.
ABSTRACT Background Respiratory syncytial virus (RSV), a single‐stranded negative‐sense RNA virus, causes respiratory tract infections in children and adults, leading to hospitalization and mortality. However, the national disease burden and economic impact of RSV in Thailand remain undetermined.
Kansak Boonpattharatthiti, Chonnamet Techasaensiri, Wanatpreeya Phongsamart, Pilailuk Akkapaiboon Okada, Chanthawat Patikorn, Prabda Praphasiri, Teerapon Dhippayom, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

, 2023
International audienceAbstract In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in ...
Amanda Leach, Wählby Hamrén, Ulrika, Mankad, Vaishali, Cabañas, Fernando, Fernando Cabañas, Domachowske, Joseph, Nguyen, Kim A, Kubiak, Robert J, Atanasova, Victoria, Victoria Atanasova, Furuno, Kenji, Robert J Kubiak, Ulrika Wählby Hamrén, Kubiak, Robert, Therese Takas, Leach, Amanda, Banu, Irfana, Nguyen, Kim An, Manish Shroff, Chang, Yue, Kenji Furuno, Kim A Nguyen, Shroff, Manish, Takas, Therese, Joseph B Domachowske, Vaishali S Mankad, Irfana Banu, Tonya Villafana, Yue Chang, Domachowske, Joseph B, Mankad, Vaishali S, Villafana, Tonya   +31 more
core   +1 more source

Efectividad de la inmunización con nirsevimab en neonatos para prevenir hospitalizaciones por virus respiratorio sincitial durante dos temporadas en Navarra

Anales del Sistema Sanitario de Navarra
Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año ...
Noelia Vera-Punzano, Ana Navascués, Leticia Armendáriz, Natividad Viguria, Mercedes Herranz-Aguirre, Manuel García Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria, Iván Martínez-Baz, Carmen Ezpeleta, Guillermo Ezpeleta, Jesús Castilla   +11 more
doaj   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

New England Journal of Medicine, 2020
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.In this trial ...
Pamela Griffin M., Yuan Y., Takas T., Domachowske J. B., Madhi S. A., Manzoni P., Simoes E. A. F., Esser M. T., Khan A. A., Dubovsky F., Villafana T., DeVincenzo J. P.   +11 more
openaire   +5 more sources